High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab

Acta Haematologica

Volumn 126, Issue 1, 2011, Pages 44-51

  Gaudio, Francesco ^a   Giordano, Annamaria ^a   Perrone, Tommasina ^a   Pastore, Domenico ^a   Curci, Paola ^a   Delia, Mario ^a   Napoli, Anna ^a   De'Risi, Clara ^a   Spina, Alessandro ^a   Ricco, Rosalia ^a   Liso, Vincenzo ^a   Specchia, Giorgina ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Chemotherapy; Lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 79952826397     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000324206     Document Type: Article

References (36)

1. De Paepe P, De Wolf-Peeters C: Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising sev-eral distinct clinicopathological entities. Leukemia 2007; 21: 37-43. (Pubitemid 44921832)
2. Fisher SG, Fisher RI: The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23: 6524-6534. (Pubitemid 39265515)
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J: Lym-phoma classification - from controversy to consensus: the REAL and WHO Classifica-tion of lymphoid neoplasms. Ann Oncol 2000; 11:3-10.
4. Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical prac-tice and translational research. Hematol Am Soc Hematol Educ Program. 2009;1:523-531.
5. Project TIN-HsLPF: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tib-shirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warn-ke R Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma iden-tified by gene expression profiling. Nature 2000; 403:503-511. (Pubitemid 30082188)
7. Rosenwald A, Staudt LM: Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003; 44: 41-47.
8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Colt-man CA Jr, Miller TP: Comparison of a stan-dard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006. (Pubitemid 23095683)
9. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C: Treat-ment of patients with low grade B-cell lym-phoma with the combination of chime-ric anti-CD-20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276. (Pubitemid 29022402)
10. Coiffier B, Lepage E, Briere J, Herbrecht R Tilly H, Bouabdallah R Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Leder-lin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242. (Pubitemid 34438862)
11. Feugier P, Van Hoof A, Sebban C, Solal- Cel-igny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126. (Pubitemid 46211317)
12. Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R MacPherson N O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM: Introduc-tion of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Co-lumbia. J Clin Oncol 2005; 3:5027-5033. (Pubitemid 46224009)
13. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M: CHOP-like chemother-apy plus rituximab versus CHOP-like che-motherapy alone in young patients with good prognosis diffuse large-B-cell lym-phoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
14. Sehn LH: Early detection of patients with poor risk diffuse large B-cell lymphoma. Leuk Lymphoma 2009; 1744-1747
15. McLaughlin P, Grillo-López AJ, White CA, Czuczman M, Maloney D, Alkuzweny B, Ca-banillas F: Prognostic factors for non-Hodg-kins lymphoma patients treated with chemo-therapy may not predict response duration in patients treated with immunotherapy: rituximab experience. Proc Annu Meet Am Assoc Cancer Res 1999; 40: 718(No 4746).
16. Sehn LH: Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2006;1:295-302.
17. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R Reyes F, Gaulard P, Coiffier B: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resis-tance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLB-CL). Blood 2003; 101:4279-4284. (Pubitemid 36857789)
18. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Fel-gar RE, His ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective cor-relative study. Blood 2006; 107: 4207-4213. (Pubitemid 43801342)
19. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E: Mab-Thera International Trial (MInT) Group. Prognostic significance of maximum tu-mour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lympho-ma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9: 435-444.
20. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM: The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the Standard IPI for patients with DLBCL treated with R-CHOP. Blood 2007; 109:1857-1861. (Pubitemid 46348180)
21. Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP, Loong EL, Sng I, Hwan-Cheong TL, Ang MK, Ngeow J, Tham CK, Tan MH, Lim ST: Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008; 49:462-469. (Pubitemid 351298329)
22. Yang S, Yu Y, Jun-Min L, Jian-Qing M, Qiu-Sheng C, Yu C, Wei-Li Z, Jian-Hua Y, Hui-Jin Z, Yan W, Li W, Shu C, Zhi-Xiang S: Reas-sessment of the prognostic factors of interna-tional prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. Ann Hematol 2009; 88:863-869.
23. Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, Savage K, Chhanabhai M, Gascoyne RD, Connors JM, Sehn LH: Prognostic implications of extranodal in-volvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincris-tine, and prednisone. Leuk Lymphoma 2010; 51: 1658-1667.
24. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN: Prog-nostic Significance of the Ki-67-Associated Proliferative Antigen in Aggressive Non-Hodgkin's Lymphomas: A prospective Southwest Oncology Group Trial. Blood 1994; 83:1460-1466. (Pubitemid 24081556)
25. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Spon-sored International Working Group. J Clin Oncol 2000; 18: 2351.
26. Cheson BD, Pfistner B, Juweid ME, Gas-coyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Conno JM, Federico M, Diehl V: Revised response criteria for ma-lignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
27. Czuczman MS, Grillo-Lopez AJ, Alkuzweny B, Weaver R, Larocca A, McLaughlin P: Prognostic factors for non-Hodgkin's lym-phoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 2006: 47: 1830-1840. (Pubitemid 44649768)
28. Saito B, Shiozawa E, Yamochi-Onizuka T, Adachi D, Nakamaki T, Tomoyasu S, Omine M, Mitsuya T, Takimoto M, Ota H: Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathol Int 2004; 54:667-674. (Pubitemid 39297291)
29. Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H, Andersson PO: Low rather than high Ki-67 protein expres-sion is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008; 49:1501-1509.
30. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD: Bulky dis-ease is an adverse prognostic factor in pa-tients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincris-tine, and prednisone with or without radio-therapy for aggressive lymphoma. Cancer 2001; 91: 2440-2446. (Pubitemid 32552833)
31. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S: The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphomas varies accord-ing to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006; 76:473-480.
32. Lossos IS, Morgensztern D: Prognostic bio-markers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995-1007. (Pubitemid 46638855)
33. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, Richter LC, Miller TP: Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the mono-clonal antibody Ki-67. Blood 1988; 71: 1157-1160.
34. Gascoyne RD, Adomat SA, Krajewski S, Kra-jewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rear-rangement in diffuse aggressive non-Hodg-kin's lymphoma. Blood 1997; 90: 244-251. (Pubitemid 27276568)
35. Jazirehi AR, Bonavida B: Cellular and mo-lecular signal transduction pathways modu-lated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: impli-cations in chemosensitization and therapeu-tic intervention. Oncogene 2005; 24:2121-2143. (Pubitemid 40516580)
36. Alas S, Emmanoulides, Bonavida B: Inhibi-tion of Interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitation of B-cell Non-Hodgkin's Lymphoma to apop-tosis. Clin Cancer Res 2001; 7:709-723. (Pubitemid 32707998)